First in human safety study of FX-322 in adults undergoing cochlear implantation.

Trial Profile

First in human safety study of FX-322 in adults undergoing cochlear implantation.

Completed
Phase of Trial: Phase I

Latest Information Update: 17 Apr 2018

At a glance

  • Drugs FX 322 (Primary)
  • Indications Sensorineural hearing loss
  • Focus Adverse reactions; First in man; Pharmacokinetics
  • Sponsors Frequency Therapeutics
  • Most Recent Events

    • 21 Dec 2017 Primary endpoint has been met. (To assess diffusion of FX-322 from the middle ear, across the oval and round window membranes, and into the cochlear fluid (perilymph). The concentration of FX-322 will be analysed from the perilymph fluid and blood plasma by standard laboratory methods.), as reported in a Frequency Therapeutics Media Release.
    • 21 Dec 2017 Results published in the Frequency Therapeutics Media Release
    • 21 Dec 2017 Status changed from recruiting to completed, as reported in a Frequency Therapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top